Related Experiment Video

Updated: Apr 16, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

941

INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia

I Dzneladze1, R He2, J F Woolley3

  • 11] Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.

Leukemia
|March 5, 2015
PubMed

Insights

High levels of inositol polyphosphate-4-phosphatase, type-II (INPP4B) indicate poor prognosis in acute myeloid leukemia (AML). INPP4B is a novel prognostic biomarker and potential therapeutic target for AML patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Inositol polyphosphate-4-phosphatase, type-II (INPP4B) has a known tumor-suppressive role in epithelial cancers.
  • The role of INPP4B in hematological malignancies, specifically acute myeloid leukemia (AML), remains largely unexplored.

Purpose of the Study:

  • To investigate the prognostic significance of INPP4B expression in AML patients.
  • To elucidate the functional role of INPP4B in the biology of leukemic cells.

Main Methods:

  • Analysis of INPP4B expression levels in AML patient cohorts.
  • Correlation of INPP4B expression with clinical outcomes, including response to therapy and survival.
  • In vitro studies involving overexpression of INPP4B in AML cell lines to assess its impact on cellular behavior.
  • Multivariate analyses to determine INPP4B as an independent prognostic factor.

Main Results:

  • AML patients with high INPP4B expression (INPP4B(high)) exhibited poor response to induction therapy, shorter event-free survival, and shorter overall survival.
  • INPP4B(high) served as an independent predictor of poor prognosis, outperforming established biomarkers like FLT3-ITD and NPM1.
  • INPP4B(high) effectively stratified risk in AML patients with normal cytogenetics.
  • In vitro, INPP4B overexpression in AML cell lines enhanced colony formation, conferred chemotherapy resistance, and promoted proliferation in a phosphatase-dependent, Akt-independent manner.

Conclusions:

  • High INPP4B expression is associated with adverse outcomes in AML, suggesting an oncogenic role.
  • INPP4B represents a novel prognostic biomarker for AML, potentially improving current predictive models.
  • INPP4B warrants further investigation as a potential therapeutic target in AML.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.6K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K